Paid Clinical Trials Tulsa
Discover 192 paid clinical trials in Tulsa. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06393374
Conditions
Triple-Negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
sac-TMT
Capecitabine
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
Sponsor:
CinPhloro Pharma, LLC
Location:
Code:
NCT06153420
Conditions
Irritable Bowel Syndrome With Diarrhea
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CIN-103
Placebo
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Sponsor:
Bristol-Myers Squibb
Location:
Code:
NCT06003426
Conditions
Idiopathic Pulmonary Fibrosis
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
BMS-986278
BMS-986278 Placebo
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
Sponsor:
Escient Pharmaceuticals, Inc
Location:
Code:
NCT06077773
Conditions
Chronic Spontaneous Urticaria
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Oral EP262
Placebo
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT03486873
Conditions
Solid Tumors
Hematologic Malignancies
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Standard of Care (SOC)
Lenvatinib
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03866382
Conditions
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography
Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis
Sponsor:
Lipogems International spa
Location:
Code:
NCT06121882
Conditions
Knee Osteoarthritis
Osteo Arthritis Knee
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Microfragmented Adipose Tissue derived using the Lipogems® System
Saline Injection
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Sponsor:
LEO Pharma
Location:
Code:
NCT06311682
Conditions
Atopic Dermatitis
Eligibility Criteria
Sex: All
Age: 6 - 11
Healthy Volunteers: Not accepted
Interventions
Tralokinumab + TCS
Placebo + TCS
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004
Sponsor:
Intec Pharma Ltd.
Location:
Code:
NCT02615873
Conditions
Parkinson's Disease
Eligibility Criteria
Sex: All
Age: 30 - 70+
Healthy Volunteers: Not accepted
Interventions
Accordion Pill™ Carbidopa/Levodopa